0000000001050026

AUTHOR

7

showing 3 related works from this author

Performance of the ALICE experiment at the CERN LHC

2014

ALICE is the heavy-ion experiment at the CERN Large Hadron Collider. The experiment continuously took data during the first physics campaign of the machine from fall 2009 until early 2013, using proton and lead-ion beams. In this paper we describe the running environment and the data handling procedures, and discuss the performance of the ALICE detectors and analysis methods for various physics observables.

p-p and Pb-Pb and p-Pb collisions at the LHCPhysics::Instrumentation and Detectors01 natural sciences07.05.-tParticle identificationHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)ALICEData acquisition29.40.-nAtomic and Molecular Physics[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Nuclear Experiment (nucl-ex)Nuclear ExperimentNuclear ExperimentAnalysis methodPhysicsLarge Hadron ColliderLHC; ALICE; heavy-ion collisions; particle detectors.Physicsparticle detectorsAtomic and Molecular Physics and Optics3. Good healthPRIRODNE ZNANOSTI. Fizika.LHCParticle Physics - Experimentheavy-ion collisionNuclear and High Energy PhysicsParticle physicsGroup method of data handlingFOS: Physical sciences[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]Nuclear physicsLHC; ALICE; heavy-ion collisions; particle detectors29.85.-c0103 physical sciences010306 general physicsALICE; Heavy-ion collisions; LHC; Particle detectors; Atomic and Molecular Physics and Optics; Astronomy and Astrophysics; Nuclear and High Energy Physics010308 nuclear & particles physics25.75.-qALICE experimentAstronomy and Astrophysicsheavy-ion collisionsNATURAL SCIENCES. Physics.Physics::Accelerator Physics25.75.-q; 29.40.-n; 29.85.-c; 07.05.-t; LHC ALICE heavy-ion collisions particle detectorsHigh Energy Physics::ExperimentHeavy ionALICE; Heavy-ion collisions; LHC; Particle detectorsand OpticsALICE (propellant)Detector performanceInternational Journal of Modern Physics A
researchProduct

Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study

2013

In a 24-month prospective, randomized, multicenter, open-label study, de novo liver transplant patients were randomized at 30 days to everolimus (EVR) + Reduced tacrolimus (TAC; n = 245), TAC Control (n = 243) or TAC Elimination (n = 231). Randomization to TAC Elimination was stopped prematurely due to a significantly higher rate of treated biopsy-proven acute rejection (tBPAR). The incidence of the primary efficacy endpoint, composite efficacy failure rate of tBPAR, graft loss or death postrandomization was similar with EVR + Reduced TAC (10.3%) or TAC Control (12.5%) at month 24 (difference -2.2%, 97.5% confidence interval [CI] -8.8%, 4.4%). BPAR was less frequent in the EVR + Reduced TAC…

Graft RejectionMalemTOR inhibitormedicine.medical_treatmentMedizinLiver transplantationKidneylaw.inventionAntineoplastic AgentImmunosuppressive AgentRandomized controlled triallawImmunology and AllergySirolimuPharmacology (medical)Prospective StudiestacrolimusProspective cohort studyglomerular filtration rateIncidenceGraft SurvivalMiddle AgedEuropeEverolimuTreatment OutcomeFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmTOR inhibitorsmedicine.medical_specialtyliver transplantation everolimusRandomizationAdolescentEverolimus glomerular filtration rate mTOR inhibitors renal function tacrolimusUrologyRenal functionAntineoplastic Agentschemical and pharmacologic phenomenaFollow-Up StudieYoung AdultmedicineHumansEverolimusAgedSirolimusTransplantationEverolimusDose-Response Relationship Drugbusiness.industryrenal functiontacrolimuSouth AmericaSurgeryLiver TransplantationTransplantationstomatognathic diseasesProspective StudieSirolimusNorth AmericabusinessFollow-Up Studies
researchProduct

The Italian multiple sclerosis register

2019

The past decade has seen extraordinary increase in worldwide availability of and access to several large multiple sclerosis (MS) databases and registries. MS registries represent powerful tools to provide meaningful information on the burden, natural history, and long-term safety and effectiveness of treatments. Moreover, patients, physicians, industry, and policy makers have an active interest in real-world observational studies based on register data, as they have the potential to answer the questions that are most relevant to daily treatment decision-making. In 2014, the Italian MS Foundation, in collaboration with the Italian MS clinical centers, promoted and funded the creation of the …

Register (sociolinguistics)AdultMaleKnowledge managementDatabases FactualEpidemiologymedia_common.quotation_subjectDisease epidemiologyEpidemiology; Multiple sclerosis; Quality of care; RegisterLongitudinal StudieDermatologyNOCohort StudiesMultiple sclerosisDatabases03 medical and health sciences0302 clinical medicineMultiple SclerosiHumansQuality (business)Longitudinal Studies030212 general & internal medicineRegistriesEpidemiology Multiple sclerosis Quality of care Register Adult Cohort Studies Data Collection Databases Factual Female; Humans Italy; Longitudinal Studies Male Multiple Sclerosis RegistriesQuality of careFactualmedia_commonData collectionbusiness.industryData CollectionQuality of careCorrectionEpidemiology; Multiple sclerosis; Quality of care; Register; Adult; Cohort Studies; Data Collection; Databases Factual; Female; Humans; Italy; Longitudinal Studies; Male; Multiple Sclerosis; RegistriesGeneral MedicineRegisterItalyRegister dataPsychiatry and Mental HealthObservational studyOriginal ArticleSettore MED/26 - NeurologiaFemaleBusinessNeurology (clinical)Cohort Studie030217 neurology & neurosurgeryEpidemiology; Multiple sclerosis; Quality of care; Register; 2708; Neurology (clinical); Psychiatry and Mental Health2708Human
researchProduct